Several classes of PI3K inhibitors have been developed, including isoform-specific or dual PI3K inhibitors, pan-PI3K inhibitors, and dual PI3K/mTOR inhibitors, and are currently approved or in different stages of clinical development for the treatment of both solid and hematological malignancies [76]. This evidence concerns the gene PIK3CA and hematologic disorder.